Literature DB >> 20356763

Whole tumor antigen vaccines.

Cheryl Lai-Lai Chiang1, Fabian Benencia, George Coukos.   

Abstract

Although cancer vaccines with defined antigens are commonly used, the use of whole tumor cell preparations in tumor immunotherapy is a very promising approach and can obviate some important limitations in vaccine development. Whole tumor cells are a good source of TAAs and can induce simultaneous CTLs and CD4(+) T helper cell activation. We review current approaches to prepare whole tumor cell vaccines, including traditional methods of freeze-thaw lysates, tumor cells treated with ultraviolet irradiation, and RNA electroporation, along with more recent methods to increase tumor cell immunogenicity with HOCl oxidation or infection with replication-incompetent herpes simplex virus. Copyright 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356763      PMCID: PMC3119500          DOI: 10.1016/j.smim.2010.02.004

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  176 in total

Review 1.  Virus augmentation of the antigenicity of tumor cell extracts.

Authors:  F C Austin; C W Boone
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

2.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.

Authors:  F Stephen Hodi; Martin C Mihm; Robert J Soiffer; Frank G Haluska; Marcus Butler; Michael V Seiden; Thomas Davis; Rochele Henry-Spires; Suzanne MacRae; Ann Willman; Robert Padera; Michael T Jaklitsch; Sridhar Shankar; Teresa C Chen; Alan Korman; James P Allison; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-07       Impact factor: 11.205

3.  CD4+CD25+ regulatory T cells that secrete TGFbeta and IL-10 are preferentially induced by a vaccine vector.

Authors:  S Farzana Hussain; Yvonne Paterson
Journal:  J Immunother       Date:  2004 Sep-Oct       Impact factor: 4.456

4.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells.

Authors:  Zhen Su; Jens Dannull; Axel Heiser; Donna Yancey; Scott Pruitt; John Madden; Doris Coleman; Donna Niedzwiecki; Eli Gilboa; Johannes Vieweg
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

5.  Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients.

Authors:  Mary L Disis; Vivian Goodell; Kathy Schiffman; Keith L Knutson
Journal:  J Clin Immunol       Date:  2004-09       Impact factor: 8.317

6.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

7.  Class B scavenger receptors CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein.

Authors:  Gunther Marsche; Robert Zimmermann; Seikoh Horiuchi; Narendra N Tandon; Wolfgang Sattler; Ernst Malle
Journal:  J Biol Chem       Date:  2003-09-10       Impact factor: 5.157

8.  Active specific immunotherapy with vaccinia colon oncolysate enhances the immunomodulatory and antitumor effects of interleukin-2 and interferon alpha in a murine hepatic metastasis model.

Authors:  P J Arroyo; J A Bash; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

9.  Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes.

Authors:  Martin R Müller; Frank Grünebach; Alessio Nencioni; Peter Brossart
Journal:  J Immunol       Date:  2003-06-15       Impact factor: 5.422

10.  Molecular identification of a danger signal that alerts the immune system to dying cells.

Authors:  Yan Shi; James E Evans; Kenneth L Rock
Journal:  Nature       Date:  2003-09-07       Impact factor: 49.962

View more
  65 in total

Review 1.  Translating tumor antigens into cancer vaccines.

Authors:  Luigi Buonaguro; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro
Journal:  Clin Vaccine Immunol       Date:  2010-11-03

Review 2.  Biomaterials for vaccine-based cancer immunotherapy.

Authors:  Rui Zhang; Margaret M Billingsley; Michael J Mitchell
Journal:  J Control Release       Date:  2018-10-09       Impact factor: 9.776

3.  Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer.

Authors:  Cassandra E Callmann; Lisa E Cole; Caroline D Kusmierz; Ziyin Huang; Dai Horiuchi; Chad A Mirkin
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

Review 4.  Immunotherapy in Gynecologic Cancers: Are We There Yet?

Authors:  Janelle B Pakish; Amir A Jazaeri
Journal:  Curr Treat Options Oncol       Date:  2017-08-24

5.  A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Authors:  Cheryl Lai-Lai Chiang; Lana E Kandalaft; Janos Tanyi; Andrea R Hagemann; Gregory T Motz; Nikolaos Svoronos; Kathleen Montone; Gina M Mantia-Smaldone; Lori Smith; Harvey L Nisenbaum; Bruce L Levine; Michael Kalos; Brian J Czerniecki; Drew A Torigian; Daniel J Powell; Rosemarie Mick; George Coukos
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

6.  Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Authors:  Jian Yan; Panyupa Pankhong; Thomas H Shin; Nyamekye Obeng-Adjei; Matthew P Morrow; Jewell N Walters; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Cancer Immunol Res       Date:  2013-07-17       Impact factor: 11.151

Review 7.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Glycan array analysis of the antigen repertoire targeted by tumor-binding antibodies.

Authors:  Jeffrey C Gildersleeve; Baomei Wang; Samuel Achilefu; Zhude Tu; Mai Xu
Journal:  Bioorg Med Chem Lett       Date:  2012-09-24       Impact factor: 2.823

Review 9.  Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.

Authors:  Mikio Kajihara; Kazuki Takakura; Tomoya Kanai; Zensho Ito; Yoshihiro Matsumoto; Shigetaka Shimodaira; Masato Okamoto; Toshifumi Ohkusa; Shigeo Koido
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

10.  Tumor cell-derived microparticles: a new form of cancer vaccine.

Authors:  Huafeng Zhang; Bo Huang
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.